Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma

Wei, Lihui; Miao, Yubin; Gallazzi, Fabio; Quinn, Thomas P.; Welch, Michael J.; Vāvere, Amy L.; Lewis, Jason S.

doi:10.1016/j.nucmedbio.2007.07.003

Cited by 49 publications

(42 citation statements)

References 48 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,27,28 Hence, 15 mg of L -lysine was co-injected with either 99m Tc-RGD-Lys-(Arg 11 )CCMSH or 99m Tc-RGD-Arg-(Arg 11 )CCMSH at 2 h post-injection to determine whether the non-specific renal uptakes of 99m Tc-RGD-Lys-(Arg 11 )CCMSH and 99m Tc-RGD-Arg-(Arg 11 )CCMSH were associated with the electrostatic interaction between the peptide and kidney cells. As we anticipated, co-injection of L -lysine reduced the renal uptake of 99m Tc-RGD-Lys-(Arg 11 )CCMSH by 52.1% (p<0.05) and decreased the renal uptake of 99m Tc-RGD-Arg-(Arg 11 )CCMSH by 27.7% (p<0.05) without affecting the tumor uptakes, demonstrating that the electrostatic interaction played an important role in the non-specific renal uptakes of 99m Tc-RGD-Lys-(Arg 11 )CCMSH and 99m Tc-RGD-Arg-(Arg 11 )CCMSH.…”

Section: Discussionmentioning

confidence: 99%

Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide

Yang

Guo

Padilla

et al. 2010

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to reduce the non-specific renal uptake of Arg-Gly-Asp (RGD)-conjugated alpha-melanocyte stimulating hormone (α-MSH) hybrid peptide through structural modification or L-lysine co-injection. The RGD motif {cyclic(Arg-Gly-Asp-DTyr-Asp)} was coupled to [Cys 3,4,10 , D-Phe 7 , Arg 11 ]α-MSH 3-13 {(Arg 11 )CCMSH} through the Arg linker (substituting the Lys linker) to generate a novel RGD-Arg-(Arg 11 )CCMSH hybrid peptide. The melanoma targeting and pharmacokinetic properties of 99m Tc-RGD-Arg-(Arg 11 )CCMSH were determined in B16/F1 melanoma-bearing C57 mice. The effect of L-lysine co-injection on the renal uptake was determined through the co-injection of L-lysine with 99m Tc-RGD-Arg-(Arg 11 )CCMSH or 99m Tc-RGD-Lys-(Arg 11 )CCMSH. Replacement of the Lys linker with an Arg linker exhibited a profound effect in reducing the non-specific renal uptake of 99m Tc-RGD-Arg-(Arg 11 )CCMSH, as well as increasing the tumor uptake of 99m Tc-RGD-Arg-(Arg 11 )CCMSH compared to 99m Tc-RGD-Lys-(Arg 11 )CCMSH. 99m Tc-RGD-Arg-(Arg 11 )CCMSH exhibited high tumor uptake (21.41 ± 3.74% ID/g at 2 h post-injection) and prolonged tumor retention (6.81 ± 3.71% ID/g at 24 h post-injection) in B16/F1 melanoma-bearing mice. The renal uptake values of 99m Tc-RGD-Arg-(Arg 11 )CCMSH were 40.14-64.08% of those of 99m Tc-RGD-Lys-(Arg 11 )CCMSH (p<0.05) at 0.5, 2, 4 and 24 h post-injection. Co-injection of L-lysine was effective in decreasing the renal uptakes of 99m Tc-RGD-Arg-(Arg 11 )CCMSH by 27.7% and 99m Tc-RGD-Lys-(Arg 11 )CCMSH by 52.1% at 2 h post-injection. Substitution of the Lys linker with an Arg linker dramatically improved the melanoma uptake and reduced the renal uptake of 99m Tc-RGD-Arg-(Arg 11 )CCMSH, warranting the further evaluation of 188 Re-labeled RGD-Arg-(Arg 11 )CCMSH as a novel MC1 receptor-targeting therapeutic peptide for melanoma treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Replacement of the Lys linker with an Arg linker resulting in improved melanoma uptake and reduced renal uptake of Tc-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide

Yang

Guo

Padilla

et al. 2010

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Up to now, many variants based on α-MSH and its biologically stable synthetic analog Ac-[Nle 4 , DPhe 7 ]-α-MSH (NDP-MSH), which binds to all melanocortin receptors except for MC2R with similar affinity, has been synthesized [100]. Among them are linear and cyclic (for fixation the most favorable conformation for receptor binding) peptides conjugated with chelators for 111 In [101–110], 99m Tc [101, 109, 111–115], and 67 Ga [116] for diagnostics using single photon emission computed tomography (SPECT), and also for 18 F [117–119], 68 Ga [110, 116, 120, 121], 64 Cu [122, 123], and 86 Y [122] for positron emission tomography (PET) diagnostics. Gene therapy using Na-I symporter (NIS) is another approach exploiting MC1R–specific ligands [124].…”

Section: Development Of Diagnostic and Therapeutic Agents Based On α-mentioning

confidence: 99%

Malignant melanoma and melanocortin 1 receptor

Rosenkranz

Slastnikova

Durymanov

et al. 2013

Biochemistry Moscow

View full text Add to dashboard Cite

The conventional chemotherapeutic treatment of malignant melanoma still remains poorly efficient in most cases. Thus the use of specific features of these tumors for development of new therapeutic modalities is highly needed. Melanocortin receptor-1 (MC1R) overexpression on the cell surface of the vast majority of human melanomas, making MC1R a valuable marker of these tumors, is one of these features. Naturally, MC1R plays a key role in skin protection against damaging ultraviolet radiation by regulating eumelanin production. MC1R activation is involved in regulation of melanocyte cell division. This article reviews the peculiarities of regulation and expression of MC1R, melanocytes, and melanoma cells, along with the possible connection of MC1R with signaling pathways regulating proliferation of tumor cells. MC1R is a cell surface endocytic receptor, thus considered perspective for diagnostics and targeted drug delivery. A number of new therapeutic approaches that utilize MC1R, including endoradiotherapy with Auger electron and α- and β-particle emitters, photodynamic therapy, and gene therapy are now being developed.

show abstract

“…A group of investigators at Washington University in St. Louis, Missouri, reported tumor uptake in mice as well as the biodistribution of a 68 Ga-labeled DOTA-rhenium-cyclized a-MSH analog (24). This agent showed promise for the early detection of malignant melanoma.…”

Section: Peptide Imaging Of Melanomamentioning

confidence: 99%